Compounds > valsartan
Page last updated: 2024-08-24

valsartan and omapatrilat

valsartan has been researched along with omapatrilat in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Basile, JN; Bloch, MJ1
Armstrong, SR; Budman, J; Cheruvu, M; Hegde, LG; Hegde, SS; Hill, CM; Klein, U; Lane, CE; Olsufka, R; Park, T; Renner, T; Sandvik, ER; Thibodeaux, H; Yu, C1
Baigent, C; Haynes, R; Judge, P; Landray, MJ1
Lang, CC; Singh, JS1
Mookherjee, S; Safar, ME; Smulyan, H1
Brown, NJ; Hubers, SA1
Brozena, S; Jessup, M; Owens, AT1
Lang, H; Melk, A; Schmidt, BMW; Vollmer Barbosa, C1

Reviews

6 review(s) available for valsartan and omapatrilat

ArticleYear
Neprilysin inhibition in chronic kidney disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:5

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan

2015
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
    Vascular health and risk management, 2015, Volume: 11

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Indans; Natriuretic Peptide, Brain; Neprilysin; Propionates; Pyridines; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Stroke Volume; Tetrazoles; Thiazepines; Valsartan

2015
The two faces of hypertension: role of aortic stiffness.
    Journal of the American Society of Hypertension : JASH, 2016, Volume: 10, Issue:2

    Topics: Aging; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aorta; Arteriosclerosis; Biphenyl Compounds; Blood Pressure; Diastole; Drug Combinations; Humans; Hypertension; Microcirculation; Prevalence; Pulse Wave Analysis; Pyridines; Risk Factors; Systole; Tetrazoles; Thiazepines; Valsartan; Vascular Resistance; Vascular Stiffness

2016
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Circulation, 2016, Mar-15, Volume: 133, Issue:11

    Topics: Abnormalities, Drug-Induced; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bradykinin; Contraindications; Drug Combinations; Drug Costs; Drug Synergism; Enalapril; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Hypertension; Kidney; Multicenter Studies as Topic; Natriuretic Peptides; Neprilysin; Pregnancy; Prodrugs; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Thiazepines; Valsartan

2016
Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
    Annual review of medicine, 2017, 01-14, Volume: 68

    Topics: Alzheimer Disease; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Selection; Pyridines; Stroke Volume; Tetrazoles; Thiazepines; Valsartan

2017
Renal events in patients receiving neprilysin inhibitors: a systematic review and meta-analysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022, 11-23, Volume: 37, Issue:12

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Humans; Hyperkalemia; Neprilysin; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Valsartan

2022

Trials

1 trial(s) available for valsartan and omapatrilat

ArticleYear
Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone.
    Journal of clinical hypertension (Greenwich, Conn.), 2010, Volume: 12, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Neprilysin; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Valsartan

2010

Other Studies

1 other study(ies) available for valsartan and omapatrilat

ArticleYear
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:4

    Topics: Angioedema; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Indans; Male; Neprilysin; Propionates; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Thiazepines; Valine; Valsartan

2011